Remove Hormones Remove Research Remove Sales
article thumbnail

Neurocrine Biosciences’ Crenessity Approved as First New Treatment in Decades for Rare Genetic Disorder CAH

XTalks

CAH is a group of rare genetic disorders affecting the adrenal glands, which produce essential hormones like cortisol, aldosterone and androgens. The most common form of CAH, 21-hydroxylase deficiency, disrupts hormone production, leading to cortisol deficiency and an overproduction of androgens. billion in revenue by 2024.

Genetics 116
article thumbnail

Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate

XTalks

billion, primarily linked to initiating Phase III trials for petrelintide as a stand-alone therapy, with sales-based milestones that could push the total value to $5.3 Amylin, a hormone co-secreted with insulin, plays a key role in regulating appetite by enhancing leptins effects the hormone that signals fullness after eating.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

UK approves prescription-only melatonin drug for childhood ADHD

Pharmaceutical Technology

The hormone is produced endogenously in the body by the pineal gland. When light is detected by the retina, it causes the pineal gland to inhibit melatonin release, preventing the feelings of sleepiness associated with the hormone. In 1995, the UK government classified it as a medicine making its over-the-counter sale illegal.

Drugs 147
article thumbnail

Povorcitinib Phase III Results Stir Mixed Signals for Incyte and Investors

XTalks

Standard treatment strategies include combinations of antibiotics, hormonal therapies and biologic agents most notably adalimumab (Humira), the only FDA-approved biologic for moderate to severe cases while surgery remains an option for advanced disease.

Trials 59
article thumbnail

Bayer plans to scale back women’s health R&D

Pharmaceutical Technology

Bayer has announced that it will shift the focus of its drug research away from women’s health to four core therapeutic areas: oncology, cardiovascular, neurology and rare diseases/immunology.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

However, there has recently been a boom in interest and research in anti-obesity therapeutics. We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field.

Drugs 264
article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

However, there has recently been a boom in interest and research in anti-obesity therapeutics. We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Over the past few years, there has been a boom in anti-obesity drug development, with major companies achieving substantial sales in the field.

Drugs 246